PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.10, 2008-10, pp. : 1465-1471

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus

By Salvadó Laia Serrano-Marco Lucía Barroso Emma Palomer Xavier Vázquez-Carrera Manuel

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 2, 2012-02 ,pp. : 209-223

Informa Healthcare

Access to resources Recommend Favorite

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk

Current Pharmaceutical Design, Vol. 23, Iss. 6, 2017-03 ,pp. : 894-902

Bentham Science Publishers

Access to resources Recommend Favorite

Design, Synthesis and Evaluation of Peroxisome Proliferator-Activated Receptor /&bgr;Dual Agonists for the Treatment of Type 2 Diabetes

Letters in Drug Design & Discovery, Vol. 4, Iss. 1, 2007-01 ,pp. : 27-32

Bentham Science Publishers

Access to resources Recommend Favorite

Liraglutide looking good in type 2 diabetes

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

PPAR- agonists: therapeutic role in diabetes, inflammation and cancer

By Murphy G.J. Holder J.C.

Trends in Pharmacological Sciences, Vol. 21, Iss. 12, 2000-12 ,pp. : 469-474

Elsevier

Access to resources Recommend Favorite